98%
921
2 minutes
20
Background: In 2015, the Advisory Committee on Immunization Practices recommended Meningococcal B vaccination for healthy 16- to 23-year-olds based on shared clinical decision-making between the patient and the provider. There has been some confusion regarding how to implement this recommendation.
Methods: Through discussions among the authors, a review of relevant literature, and consultation with vaccine experts, we developed educational materials for providers that included a patient handout to help initiate and guide conversations leading to shared clinical decision-making for the Meningococcal B vaccine. Materials were distributed to 88 health care providers who subsequently completed surveys to evaluate their impressions of the materials and the utility of the materials for clinical practice.
Results: The survey results from the 88 providers revealed that they valued the materials; 93% percent indicated they would share these materials with colleagues, and 95% agreed or strongly agreed that they would share these materials with patient families. Responses to an open-ended question indicate that some providers initiated discussions regarding the Meningococcal B vaccine in ways that truncated conversation rather than encouraging a shared decision-making process.
Conclusions: Overall, the materials developed and implemented for this project support the initiation of, and help standardize provider conversations regarding, Meningococcal B vaccination for healthy adolescents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.acap.2022.01.006 | DOI Listing |
Overview: We analysed Australian Immunisation Register (AIR) data, predominantly for National Immunisation Program funded vaccines, as at 2 April 2023 for children, adolescents and adults, focusing on the calendar year 2022 and on trends from previous years. This report aims to provide comprehensive analysis and interpretation of vaccination coverage data to inform immunisation policy and programs.
Children: Fully vaccinated coverage in Australian children in 2022 was 0.
J Epidemiol Glob Health
September 2025
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Arch Dis Child
September 2025
Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Hepatitis B virus (HBV) is a potentially chronic infection that can be transmitted from mother to child with the risk of developing cirrhosis, liver failure and hepatocellular carcinoma. There is a safe and effective vaccine to prevent vertical transmission that is recommended to be given as soon as possible after birth and within 24 hours.When a woman with HBV refuses the birth dose of HBV vaccine for her baby, infectious diseases and safeguarding teams are asked to provide urgent opinions on whether this crosses the threshold for triggering child protection mechanisms.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Merck & Co. Inc., Rahway, NJ, USA.
Invasive disease caused by type b (Hib) is a major health concern, particularly in children under 5 years of age and vulnerable populations. Use of Hib conjugate vaccines has significantly reduced the incidence of Hib disease. Among these, the polyribosylribitol phosphate-outer membrane protein complex (PRP-OMPC) conjugate has demonstrated uniquely robust immunogenicity in infants compared to PRP conjugated to tetanus toxoid.
View Article and Find Full Text PDFCan Commun Dis Rep
August 2025
Division des maladies infectieuses, Centre hospitalier de l'Université de Montréal, Montréal, QC.
Background: In Canada, the burden of gonorrhea has been increasing steadily over the last decade with emerging multi-drug-resistant strains. There is a high genomic similarity between and .
Methods: Review of published studies and on-going trials with the four-component meningococcal serogroup B vaccine (4CMenB-Bexsero®).